Listen to this Post
Introduction
Apple has officially rolled out watchOS 11.6.1, a highly anticipated update that reintroduces the Blood Oxygen app for certain Apple Watch users in the United States. This marks the first time since late 2023 that new Apple Watch hardware can once again measure and track blood oxygen levels—although in a slightly different way. The change comes after a lengthy patent dispute that temporarily removed the feature from newer models, leaving many users frustrated. Now, with a clever technical workaround, Apple is restoring one of the most popular health tools to its latest wearables.
the Original
Apple’s latest update, watchOS 11.6.1, works in sync with iOS 18.6.1 to bring back the Blood Oxygen app for Apple Watch Series 9, Series 10, and Apple Watch Ultra 2 models sold in the U.S. These watches lost the feature after Apple had to disable it due to a legal battle with medical tech company Masimo over patent rights.
Previously, affected users saw a blunt message stating the app was “no longer available” and were directed to the Health app for more details. Now, Apple has redesigned the function so that while the watch still collects sensor data, the actual processing happens on the paired iPhone, with results displayed in the Health app. This is less convenient than having instant readings on the watch but restores access to blood oxygen data for those who had none at all.
The new method also supports background oxygen measurements, meaning your device can still track trends over time. Apple confirms this feature is only available to U.S. customers without the original version of the Blood Oxygen app.
Updates to watchOS 11.6.1 can be installed through the Watch app on iPhone by navigating to General > Software Update—but only after updating to iOS 18.6.1. Notably, iOS 26 and watchOS 26, still in beta, do not yet include this workaround, and since there’s no downgrade path from beta versions, Apple fans are hoping it will appear before the official release next month.
What Undercode Say:
From a technical and strategic standpoint, Apple’s approach here is both clever and necessary. By shifting the oxygen saturation calculation process from the watch to the iPhone, Apple is sidestepping the core patent claims made by Masimo while still delivering the health data users want. This keeps Apple in compliance with legal rulings while avoiding alienating customers who purchased their premium watches expecting advanced health tracking.
The compromise, however, is not without trade-offs. On-device readings are far quicker and more convenient, whereas routing data to the iPhone introduces small delays and requires the phone to be nearby. For casual users, this may not be a big deal, but for athletes or health-conscious individuals who rely on quick readings during workouts, the change could be frustrating.
From a marketing perspective, Apple is once again reinforcing its image as a brand that finds a way to deliver, even under legal pressure. By reintroducing the feature in a new form, the company retains consumer trust and limits potential backlash from those who might otherwise feel shortchanged.
Legally, the move also buys Apple time. While the Masimo case is ongoing, the company has shown it can adapt its technology to skirt infringement claims—something that could influence settlement discussions or future licensing negotiations.
For developers, this update signals that Apple is willing to make deeper integrations between watchOS and iOS, potentially paving the way for more cross-device health analytics in the future. If this hybrid processing approach proves successful, it could become a model for how Apple handles other contested or complex health features.
Economically, this workaround is a smart cost-saving measure. Instead of issuing refunds, replacements, or costly recalls, Apple simply pushed a software update—preserving both revenue and brand image.
Looking forward, one has to wonder whether Apple will fully restore on-watch blood oxygen processing once the legal dispute resolves, or whether the iPhone-linked model will become the default. Given Apple’s focus on ecosystem integration, the latter wouldn’t be surprising.
For U.S. customers, the key takeaway is simple: the feature is back, it works, and while it’s not exactly the same as before, it’s far better than nothing. Those outside the U.S., or owners of older models unaffected by the restriction, won’t notice a change—but the precedent set here could influence how Apple rolls out future health-related updates globally.
is a victory for Apple Watch owners who have been waiting nearly a year to reclaim one of the device’s most important health tracking tools, even if it comes with a slight compromise in convenience.
Fact Checker Results ✅❌
✅ The update genuinely restores blood oxygen measurement to affected U.S. models.
✅ Apple’s workaround uses iPhone processing to avoid patent conflict.
❌ The feature is not yet available in iOS 26 or watchOS 26 beta versions.
🔮 Prediction
Given Apple’s history of refining and reintroducing features post-legal disputes, it’s likely that the on-watch Blood Oxygen app will eventually return in full once the Masimo case concludes—possibly with enhanced accuracy and integration into future health-tracking suites. Until then, expect Apple to lean heavily into cross-device health analytics, positioning the iPhone as the central hub for advanced biometric processing.
🕵️📝✔️Let’s dive deep and fact‑check.
References:
Reported By: 9to5mac.com
Extra Source Hub:
https://www.reddit.com
Wikipedia
OpenAi & Undercode AI
Image Source:
Unsplash
Undercode AI DI v2
🔐JOIN OUR CYBER WORLD [ CVE News • HackMonitor • UndercodeNews ]
📢 Follow UndercodeNews & Stay Tuned:
𝕏 formerly Twitter 🐦 | @ Threads | 🔗 Linkedin | 🦋BlueSky | 🐘Mastodon
